Literature DB >> 9068930

Combination of pravastatin and cyclosporin in transplant patients.

U Christians.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9068930     DOI： 10.2165/00003088-199732020-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  11 in total

Review 1.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

2.  Low-dose lovastatin safely lowers cholesterol after cardiac transplantation.

Authors:  J A Kobashigawa; F L Murphy; L W Stevenson; J D Moriguchi; N Kawata; P Kamjoo; E Brownfield; J Wilmarth; L Leonard; C Chuck
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

3.  Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients.

Authors:  M B Regazzi; I Iacona; C Campana; V Raddato; C Lesi; G Perani; A Gavazzi; M Viganò
Journal:  Transplant Proc       Date:  1993-08       Impact factor: 1.066

4.  Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients.

Authors:  M Arnadottir; L O Eriksson; J I Germershausen; H Thysell
Journal:  Nephron       Date:  1994       Impact factor: 2.847

Review 5.  Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.

Authors:  I Hsu; S A Spinler; N E Johnson
Journal:  Ann Pharmacother       Date:  1995 Jul-Aug       Impact factor: 3.154

Review 6.  Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression.

Authors:  S Katznelson; J A Kobashigawa
Journal:  Kidney Int Suppl       Date:  1995-12       Impact factor: 10.545

7.  Risk factors for accelerated atherosclerosis in renal transplant recipients.

Authors:  B L Kasiske
Journal:  Am J Med       Date:  1988-06       Impact factor: 4.965

Review 8.  Hyperlipidemia and transplantation: etiologic factors and therapy.

Authors:  J D Pirsch; A M D'Alessandro; H W Sollinger; S J Knechtle; A Reed; M Kalayoglu; F O Belzer
Journal:  J Am Soc Nephrol       Date:  1992-06       Impact factor: 10.121

9.  In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.

Authors:  C Transon; T Leemann; P Dayer
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

10.  [Rhabdomyolysis in patients treated with simvastatin and cyclosporin: role of the hepatic cytochrome P450 enzyme system activity].

Authors:  C Meier; C Stey; T Brack; M Maggiorini; B Risti; S Krähenbühl
Journal:  Schweiz Med Wochenschr       Date:  1995-07-11
View more
  2 in total

Review 1.  Does differing metabolism by cytochrome p450 have clinical importance?

Authors:  M H Davidson
Journal:  Curr Atheroscler Rep       Date:  2000-01       Impact factor: 5.113

Review 2.  Drug interactions of lipid-altering drugs.

Authors:  H E Bays; C A Dujovne
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.